Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of BIIB142 in Healthy Adults
NCT07133828Phase 1Recruiting
- Sponsor
- Biogen
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BIIB142 (9 cohorts), sponsored by Biogen. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants with Clinical Laboratory Abnormalities and 3 more. Started Aug 2025; status: recruiting.
02
Drugs
BIIB142
Beyond the preview
Go deeper on NCT07133828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133828.